Abstract
SCH 39304 was tested for treatment of acute or established murine pulmonary blastomycosis and was compared with ketoconazole and fluconazole in a model of acute infection. Only SCH 39304 at 25 or 50 mg/kg of body weight per day produced 100% survival for 30 days after the 20-day treatment, although only 33% of the mice were cleared of infection. SCH 39304 at 2 mg/kg/day was similar to ketoconazole at 100 mg/kg/day and to fluconazole at 10 mg/kg/day. In a model of established blastomycosis, used to evaluate long-term treatment of very sick or moribund mice, SCH 39304 at 50 mg/kg/day protected against death with a 96% cumulative 8-week survival. SCH 39304 was clearly superior on a milligram-per-kilogram basis in acute blastomycosis, and long-term treatment of more severe blastomycosis was curative.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arathoon E. G., Brummer E., Stevens D. A. Efficacy of itraconazole in blastomycosis in a murine model and comparison with ketoconazole. Mycoses. 1989;32 (Suppl 1):109–112. doi: 10.1111/j.1439-0507.1989.tb02300.x. [DOI] [PubMed] [Google Scholar]
- Brummer E., Morozumi P. A., Philpott D. E., Stevens D. A. Virulence of fungi: correlation of virulence of Blastomyces dermatitidis in vivo with escape from macrophage inhibition of replication in vitro. Infect Immun. 1981 May;32(2):864–871. doi: 10.1128/iai.32.2.864-871.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clemons K. V., Hanson L. H., Perlman A. M., Stevens D. A. Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother. 1990 May;34(5):928–930. doi: 10.1128/aac.34.5.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dismukes W. E., Stamm A. M., Graybill J. R., Craven P. C., Stevens D. A., Stiller R. L., Sarosi G. A., Medoff G., Gregg C. R., Gallis H. A. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med. 1983 Jan;98(1):13–20. doi: 10.7326/0003-4819-98-1-13. [DOI] [PubMed] [Google Scholar]
- Galgiani J. N., Stevens D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother. 1976 Oct;10(4):721–728. doi: 10.1128/aac.10.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harvey R. P., Schmid E. S., Carrington C. C., Stevens D. A. Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis. 1978 Apr;117(4):695–703. doi: 10.1164/arrd.1978.117.4.695. [DOI] [PubMed] [Google Scholar]
- Sarosi G. A., Davies S. F. Blastomycosis. Am Rev Respir Dis. 1979 Oct;120(4):911–938. doi: 10.1164/arrd.1979.120.4.911. [DOI] [PubMed] [Google Scholar]
- Stevens D. A., Brummer E., McEwen J. G., Perlman A. M. Comparison of fluconazole and ketoconazole in experimental murine blastomycosis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S304–S306. doi: 10.1093/clinids/12.supplement_3.s304. [DOI] [PubMed] [Google Scholar]
- Sugar A. M., Picard M., Noble L. Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent. Antimicrob Agents Chemother. 1990 May;34(5):896–898. doi: 10.1128/aac.34.5.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tucker R. M., Hanson L. H., Brummer E., Stevens D. A. Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother. 1989 Apr;33(4):573–575. doi: 10.1128/aac.33.4.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tucker R. M., Williams P. L., Arathoon E. G., Stevens D. A. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451–470. doi: 10.1111/j.1749-6632.1988.tb40443.x. [DOI] [PubMed] [Google Scholar]